Date updated:01-05-2007
One hundred years ago, Dr. Alois Alzheimer identified the ailment that bears his name. Scientists are now decoding the disease and testing drugs that could delay and maybe even cure Alzheimer's. Here are the public companies who are beind these drugs designed to treat, delay or prevent Alzheimer's.
According to a recent BusinessWeek article, "there are currently 4.5 million Alzheimer's patients in the U.S., and the direct and indirect costs of caring for them total more than $100 billion a year, making Alzheimer's the third most expensive illness after heart disease and cancer. Yet the federal government budgeted only $645 million for Alzheimer's research for 2007, $7 million less than the prior year. In contrast, $2.6 billion was allocated for research into HIV/AIDS, which afflicts one million Americans."

-
NRMX
N/a - $2.00
- 0.00
- $2.00
The drug Alzhemed is being produced by Neurochem. It prevents the accumulation of amyloid, a toxic protein that destroys brain cells in Alzheimer's victims. It's in Phase 3 late stage testing. The data on Alzhemed have been promising but scant. In a 2002 study it stabilized the disease in nine patients over six months, but the small sample left plenty of specialists skeptical. A clinical trial of the drug will wrap up in January, with results expected in the spring.

-
MYGN
Myriad Genetics - $23.12
- 0.00%
- $N/A
The drug Flurizan is being produced by Myriad Genetics. It inhibits the production of amyloid. It's in Phase 3 of testing with results expected next summer.

-
MEMY
N/a - $0.14
- 0.00
- $0.14
The drug MEM1003 is being produced by Memory Pharmaceuticals. It evens out the irregularities in brain levels of calcium - one of the first manifestations of Alzheimer's. It's in Phase 2 of testing.

-
WYE
Wyeth - $48.54
- 0.00%
- $N/A
The drug AAB-001 is being produced by Wyeth and Elan. It's a monoclonal antibody that seeks out and removes amyloid in the brain. It's in Phase 2 of testing.

-
LLY
Lilly Eli Co - $36.73
- -0.46%
- $36.98
The drug LY450139 is being produced by Eli Lilly. It blocks an enzyme that snips off amyloid fragments, thus reducing the production of amyloid. It's in Phase 2 of testing.

-
ELN
Elan Cp Plc Adr - $6.32
- +0.80%
- $6.45
The drug ACC-101 is being produced by Elan and Wyeth. The vaccine prompts the body's immune system to attack and remove amyloid in the brain. It's in Phase 1 (early safety tests)

-
DNA
N/a - $80.43
- 0.00
- $80.43
Nearly 60 drugs designed to modify the disease are in clinical trials. One is from AC Immune of Switzerland who recently struck a deal with biotech power player Genentech Inc. (DNA ). While known for its cancer treatments, Genentech just announced plans to invest $300 million for the rights to AC Immune's drug.
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Echo5Joker's Portfolio
- » jgroov Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Jonas Elmerraji Posted on Dec. 1, 2009 After an earnings season that has brought a significant stream of dividend-increasers, stocks are taking a step back, with jus...
By Roberto Pedone Posted on Dec. 1, 2009 Bullish and Bearish: Each week, Barron’s publishes bullish and bearish stories on a variety of stocks. We present summaries o...
Posted on Dec. 1, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is to gather as much in...
By Jonas Elmerraji Posted on Nov. 30, 2009 With Black Friday behind us and another data-heavy week ahead, it’s time to turn once again to Rocket Stocks, our list of b...
A. The only one I own : SLX,
too hard pick a winner out all of them
Below is a list of some of the companies that have their ex-dividend date Wednesday, Dec. 2, 2009. What is the ex-dividend date? The ex-dividend date of a stock is th... more
Here are some of the largest % gainers from Dec. 1, 2009. more
Analyst Upgrades or Estimate Increases for Dec. 1, 2009. Read more here. more











Comments not available